Skip to main content

Table 1 General description of study population

From: Effectiveness and safety of dual therapy with rilpivirine and boosted darunavir in treatment-experienced patients with advanced HIV infection: a preliminary 24 week analysis (RIDAR study)

 

N = 161

Age in years, median (IQR)

49 (44–53)

Male sex, n (%)

126 (78.3)

Years since HIV diagnosis, median (IQR)

17 (10–23)

CD4 nadir, median (IQR)

170 (73–290)

History of AIDS, n (%)

47 (29.3)

N° previous ART combinations, median (IQR)

5 (3–7)

Years on ART, median (IQR)

14 (6–18)

Previous ART that included, n (%):

 

NRTI

95 (59)

NNRTI

91 (56.5)

PI

128 (79.5)

II

16 (9.9)

ART strategy, n(%):

 

Triple therapy

92 (57.1)

Dual therapy

53 (32.9)

Monotherapy

16 (9.9)

Baseline VL (bVL):

 

< 50 copies/mL, n (%)

120 (74.5)

50–1000 copies/mL, n (%)

41 (25.5)

Baseline CD4 count, median (IQR)

618 (370–861)

  1. IQR: interquartile range; ART: antiretroviral therapy; NRTI: nucleoside analog reversetranscriptase inhibitors; NNRTI: non-nucleoside analog reverse-transcriptase inhibitors; PI: protease inhibitors; II: integrase inhibitors; VL: viral load